• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    3/10/25 4:05:00 PM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LCTX alert in real time by email
    • Positive 24 Month Visual Acuity Data with OpRegen® in Geographic Atrophy Patients Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit
    • Signed Services Agreement with Genentech to Further Support Ongoing OpRegen Development
    • OpRegen Received RMAT Designation from FDA
    • Completed Two Financings Totaling $44 Million in Gross Proceeds; Potential for an Additional $36 Million in Gross Proceeds Upon Full Cash Exercise of Clinical Milestone-linked Warrants
    • Initiated OPC1 Device Delivery Study in Patients with Subacute and Chronic Spinal Cord Injury
    • Hosted Annual Spinal Cord Injury Symposium with Christopher & Dana Reeve Foundation
    • Presented ReSonance™ (ANP1) Preclinical Results at 59th Annual Inner Ear Biology Workshop

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today reported its fourth quarter and full year 2024 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.

    "Throughout 2024, we made substantial progress across multiple fronts, advancing our programs, expanding collaborations, and strengthening our balance sheet to support significant anticipated milestones," stated Brian M. Culley, Lineage's CEO. "Our lead asset OpRegen continues to make progress in the ongoing GAlette Study, and we are encouraged by Roche and Genentech's commitment to the OpRegen program. Our partner's efforts to advance OpRegen for the treatment of dry AMD with GA include adding clinical sites and seeking and obtaining RMAT designation. We view these actions as positive indicators for this pioneering cell transplant and look forward to further updates on the program."

    "We anticipate our internal programs will similarly advance through important milestones during 2025," added Mr. Culley. "We will focus on conducting the recently-initiated DOSED clinical study of a novel OPC1 delivery system, advancing ReSonance for the treatment of sensorineural hearing loss, and advancing other carefully selected early-stage initiatives. In parallel, we will continue our efforts to demonstrate an in-house manufacturing capability that supports Lineage having an industry-leading position in allogeneic cell banking and production. As the power of our cell differentiation and manufacturing platforms are further demonstrated and validated, we believe that our pipeline of internally-owned assets and cell-based know-how will make us a desirable development partner and an attractive opportunity for investors."

    Select Business Highlights

    - RG6501 (OpRegen)

    • Ongoing execution of Lineage's contributions to our collaboration with Roche and Genentech, a member of the Roche Group, across multiple functional areas, including support for the ongoing Phase 2a clinical study (the "GAlette Study") in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), and expansion of the clinical study to sites in Israel.
    • Roche announced receipt of RMAT designation from the U.S. FDA for OpRegen, for the treatment of GA secondary to AMD.
    • Entered into a separate services agreement with Genentech to further support development of OpRegen, including: (i) activities to support the ongoing Phase 1/2a study and currently enrolling GAlette Study; and (ii) additional technical training and materials related to our cell therapy technology platform to support commercial manufacturing strategies.
    • Positive clinical data from long-term follow-up of patients from the Phase 1/2a clinical study of OpRegen featured at the 2024 Retinal Cell & Gene Therapy Innovation Summit.

    - OPC1

    • Submitted an Investigational New Drug Amendment (INDa) for OPC1 to enable initiation of DOSED (Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device) clinical study in subacute and chronic spinal cord patients.
      • DOSED study initiated in February 2025; UC San Diego Health named as the first participating study site.
    • Lineage and OPC1 program featured on CNN: "He was paralyzed his last day of high school. How an experimental trial is showing ‘unexpected improvement."
    • Created and hosted the 2nd Annual Spinal Cord Injury Investor Symposium in partnership with the Christopher & Dana Reeve Foundation, with additional grant support from CIRM.
      • The goals of this collaborative effort include increasing disease awareness, improving the probability of success in product development, and supporting clinical trial participation. Presenting companies have included AbbVie, Mitsubishi Tanabe, Neuralink, NervGen Pharma and ONWARD.

    - ReSonance (ANP1)

    • Preclinical results presented at 59th Annual Inner Ear Biology Workshop.
      • ReSonance manufactured by a proprietary process, developed in-house, at clinical scale, with relevant in-vitro functional activity.
      • Immediate-use, thaw-and-inject formulation durably engrafted in multiple preclinical hearing loss models.
      • ReSonance is currently being evaluated in a functional model of hearing loss through a collaboration with the University of Michigan Kresge Hearing Research Institute.

    - Corporate

    • Closed two financings totaling $44 million in gross proceeds; potential to receive an additional $36 million in gross proceeds upon the full cash exercise of OpRegen clinical milestone-linked warrants.

    Balance Sheet Highlights

    Cash, cash equivalents, and marketable securities of $47.8 million as of December 31, 2024, together with the approximate $5.5 million in net proceeds from the second closing under our November 2024 registered direct offering completed in January 2025, is expected to support planned operations into Q1 2027.

    Fourth Quarter Operating Results

    Revenues: Revenue is generated primarily from collaboration revenues, royalties, and other revenues. Total revenues for the three months ended December 31, 2024 were approximately $2.9 million, a net increase of $0.8 million as compared to $2.1 million for the same period in 2023. The increase was primarily driven by more collaboration revenue recognized from deferred revenues under the collaboration and license agreement with Roche.

    Operating Expenses: Operating expenses are comprised of research and development ("R&D") expenses and general and administrative ("G&A") expenses. Total operating expenses for the three months ended December 31, 2024 were $7.8 million, a decrease of $0.4 million as compared to $8.2 million for the same period in 2023.

    R&D Expenses: R&D expenses for the three months ended December 31, 2024 were $3.4 million, a decrease of $0.5 million as compared to $3.9 million for the same period in 2023. The net decrease was primarily driven by $1.2 million for our OPC1 program expenses and $0.2 million for other research and development expense programs, partially offset by $0.4 million for our OpRegen program expenses and $0.5 million for our preclinical programs.

    G&A Expenses: G&A expenses for the three months ended December 31, 2024 of $4.4 million were primarily in line with expenses for the same period in 2023.

    Loss from Operations: Loss from operations for the three months ended December 31, 2024 was $5.1 million, a decrease of $1.3 million as compared to $6.4 million for the same period in 2023.

    Other Income/(Expenses): Other income/(expenses) for the three months ended December 31, 2024 reflected other income of $1.8 million, compared to other income of $1.6 million for the same period in 2023. The net increase was primarily driven by changes in fair value of warrant liability, largely offset by exchange rate fluctuations related to Lineage's international subsidiaries and certain warrant-related transaction costs incurred as part of the November 2024 financing.

    Net Loss Attributable to Lineage: The net loss attributable to Lineage for the three months ended December 31, 2024 was $3.3 million, or $0.02 per share (basic and diluted), compared to a net loss of $4.8 million, or $0.03 per share (basic and diluted), for the same period in 2023.

    Full Year Operating Results

    Revenues: Revenue is generated primarily from collaboration revenues, royalties, and other revenues. Total revenues for the year ended December 31, 2024 were $9.5 million, a net increase of $0.6 million as compared to $8.9 million for the same period in 2023. The increase was primarily driven by more collaboration revenue recognized from deferred revenues under the collaboration and license agreement with Roche.

    Operating Expenses: Operating expenses are comprised of R&D expenses and G&A expenses. Total operating expenses for the year ended December 31, 2024 were $31.0 million, a decrease of $2.7 million as compared to $33.7 million for the same period in 2023.

    R&D Expenses: R&D expenses for the year ended December 31, 2024 were $12.5 million, a decrease of $3.2 million as compared to $15.7 million for the same period in 2023. The decrease was primarily driven by $2.7 million for our OPC1 program expenses, $1.1 million for our preclinical and other research and development programs. These decreases were partially offset by $0.6 million for our OpRegen program.

    G&A Expenses: G&A expenses for the year ended December 31, 2024 were $18.2 million, an increase of approximately $0.9 million as compared to $17.3 million for the same period in 2023. The net increase was primarily driven by $0.6 million for stock-based compensation expense and $0.4 million for personnel costs, partially offset by an overall decrease in costs incurred for services provided by third parties.

    Loss from Operations: Loss from operations for the year ended December 31, 2024 was $21.5 million, a decrease of $3.2 million as compared to $24.7 million for the same period in 2023.

    Other Income/(Expenses): Other income (expenses) for the year ended December 31, 2024 reflected other income of $2.9 million, compared to other income of $1.5 million for the same period in 2023. The net increase of $1.4 million was primarily driven by changes in the fair value of warrant liability, exchange rate fluctuations related to Lineage's international subsidiaries, and fair market value changes in marketable equity securities. This increase in other income was partially offset by certain warrant-related transaction costs incurred as part of the November 2024 financing, as well as the non-recurring prior year employee retention credit.

    Net Loss Attributable to Lineage: The net loss attributable to Lineage for the year ended December 31, 2024 was $18.6 million, or $0.09 per share (basic and diluted), compared to a net loss of $21.5 million, or $0.12 per share (basic and diluted), for 2023.

    Conference Call and Webcast

    Interested parties may access the conference call on March 10, 2025, by dialing (800) 715-9871 from the U.S. and Canada and should request the "Lineage Cell Therapeutics Call". A live webcast of the conference call will be available online in the Investors section of Lineage's website. A replay of the webcast will be available on Lineage's website for 30 days and a telephone replay will be available through March 17th, 2025, by dialing (800) 770-2030 from the U.S. and Canada and entering conference ID number 6707203.

    About Lineage Cell Therapeutics, Inc.

    Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, "off-the-shelf," cell therapies to address unmet medical needs. Lineage's programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient's functional activity. Lineage's neuroscience focused pipeline currently includes: (i) OpRegen®, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ReSonance™ (ANP1), an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed under a gene editing partnership. For more information, please visit www.lineagecell.com or follow the company on X/Twitter @LineageCell.

    Forward-Looking Statements

    Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as "believe," "aim," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "can," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "tend to," or the negative version of these words and similar expressions. Lineage's forward-looking statements are based upon its current expectations and beliefs and involve assumptions that may never materialize or may prove to be incorrect. Such statements include, but are not limited to, statements relating to: the potential therapeutic benefits of OpRegen in patients with GA secondary to AMD and the potential impacts of RMAT designation on Roche and Genentech's development of OpRegen or OpRegen's ultimate success; the benefits of our services agreement with Genentech and its impact on advancing the OpRegen program; the exercise of the warrants in cash upon the achievements of the clinical milestone event or otherwise prior to their expiration; the commencement of the DOSED clinical study for OPC1; the potential effect of the Spinal Cord Symposium, including accelerating development in SCI research and treatment, and raising SCI disease awareness; the potential continued development of ReSonance (ANP1); the anticipated advancement of Lineage's programs through important milestones; that potential development partners and investors will find Lineage's pipeline of internally-owned assets and cell-based know-how attractive as they are further demonstrated and validated; and that our cash, cash equivalents and marketable securities is sufficient to support our planned operations into the first quarter of 2027. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, but not limited to, the following risks: that we may need to allocate our cash to unexpected events and expenses causing us to expend our cash, cash equivalents and marketable securities more quickly than expected; that development activities, preclinical activities, and clinical trials of our product candidates may not commence, progress or be completed as expected due to many factors within and outside of our control; that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate; that Roche and Genentech may not successfully advance OpRegen or be successful in completing further clinical trials for OpRegen and/or obtaining regulatory approval for OpRegen in any particular jurisdiction; that competing alternative therapies may adversely impact the commercial potential of OpRegen; that OPC1 may not advance further in any clinical trials, and if it does, that any such clinical trials may not be successful; that the ongoing Israeli regional conflict may materially and adversely impact our manufacturing processes, including cell banking and product manufacturing for our cell therapy product candidates, all of which are conducted by our subsidiary in Jerusalem, Israel; that Lineage may not be able to manufacture sufficient clinical quantities of its product candidates in accordance with current good manufacturing practice; and those risks and uncertainties inherent in Lineage's business and other risks discussed in Lineage's filings with the Securities and Exchange Commission (SEC). Further information regarding these and other risks is included under the heading "Risk Factors" in Lineage's periodic reports with the SEC, including Lineage's most recent Annual Report on Form 10-K filed with the SEC and its other subsequent reports, which are available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. All forward-looking statements are expressly qualified in their entirety by these cautionary statements.

    LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES

    CONSOLIDATED BALANCE SHEETS

    (IN THOUSANDS)

     

     

     

    December 31, 2024

     

    December 31, 2023

    ASSETS

     

     

     

     

    CURRENT ASSETS

     

     

     

     

    Cash and cash equivalents

     

    $

    45,789

     

     

    $

    35,442

     

    Marketable securities

     

     

    2,016

     

     

     

    50

     

    Accounts receivable, net

     

     

    638

     

     

     

    745

     

    Prepaid expenses and other current assets

     

     

    2,554

     

     

     

    2,204

     

    Total current assets

     

     

    50,997

     

     

     

    38,441

     

     

     

     

     

     

    NONCURRENT ASSETS

     

     

     

     

    Property and equipment, net

     

     

    2,251

     

     

     

    2,245

     

    Operating lease right-of-use assets

     

     

    2,144

     

     

     

    2,522

     

    Deposits and other long-term assets

     

     

    614

     

     

     

    577

     

    Goodwill

     

     

    10,672

     

     

     

    10,672

     

    Intangible assets, net

     

     

    46,540

     

     

     

    46,562

     

    TOTAL ASSETS

     

    $

    113,218

     

     

    $

    101,019

     

     

     

     

     

     

    LIABILITIES AND SHAREHOLDERS' EQUITY

     

     

     

     

    CURRENT LIABILITIES

     

     

     

     

    Accounts payable and accrued liabilities

     

    $

    5,437

     

     

    $

    6,270

     

    Operating lease liabilities, current portion

     

     

    1,097

     

     

     

    830

     

    Finance lease liabilities, current portion

     

     

    55

     

     

     

    52

     

    Deferred revenues, current portion

     

     

    7,388

     

     

     

    10,808

     

    Total current liabilities

     

     

    13,977

     

     

     

    17,960

     

     

     

     

     

     

    LONG-TERM LIABILITIES

     

     

     

     

    Deferred tax liability

     

     

    273

     

     

     

    273

     

    Deferred revenues, net of current portion

     

     

    14,433

     

     

     

    18,693

     

    Operating lease liabilities, net of current portion

     

     

    1,295

     

     

     

    1,979

     

    Finance lease liabilities, net of current portion

     

     

    67

     

     

     

    91

     

    Warrant liabilities

     

     

    6,161

     

     

     

    —

     

    TOTAL LIABILITIES

     

     

    36,206

     

     

     

    38,996

     

     

     

     

     

     

    Commitments and contingencies

     

     

     

     

     

     

     

     

     

    SHAREHOLDERS' EQUITY

     

     

     

     

    Preferred shares, no par value, 2,000 shares authorized; none issued and outstanding as of December 31, 2024 and 2023

     

     

    —

     

     

     

    —

     

    Common shares, no par value, 450,000 shares authorized as of December 31, 2024 and 2023; 220,416 and 174,987 shares issued and outstanding as of December 31, 2024 and 2023, respectively

     

     

    484,722

     

     

     

    451,343

     

    Accumulated other comprehensive loss

     

     

    (2,876

    )

     

     

    (3,068

    )

    Accumulated deficit

     

     

    (403,465

    )

     

     

    (384,856

    )

    Lineage's shareholders' equity

     

     

    78,381

     

     

     

    63,419

     

    Noncontrolling deficit

     

     

    (1,369

    )

     

     

    (1,396

    )

    Total shareholders' equity

     

     

    77,012

     

     

     

    62,023

     

    TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

     

    $

    113,218

     

     

    $

    101,019

     

    LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES

    CONSOLIDATED STATEMENTS OF OPERATIONS

    (IN THOUSANDS, EXCEPT PER SHARE DATA)

     

     

     

    Year Ended December 31,

     

     

    2024

     

    2023

    REVENUES:

     

     

     

     

    Collaboration revenues

     

    $

    8,149

     

     

    $

    7,588

     

    Royalties, license and other revenues

     

     

    1,350

     

     

     

    1,357

     

    Total revenues

     

     

    9,499

     

     

     

    8,945

     

     

     

     

     

     

    OPERATING EXPENSES:

     

     

     

     

    Cost of sales

     

     

    334

     

     

     

    671

     

    Research and development

     

     

    12,472

     

     

     

    15,705

     

    General and administrative

     

     

    18,171

     

     

     

    17,302

     

    Total operating expenses

     

     

    30,977

     

     

     

    33,678

     

    Loss from operations

     

     

    (21,478

    )

     

     

    (24,733

    )

     

     

     

     

     

    OTHER INCOME (EXPENSES):

     

     

     

     

    Interest income, net

     

     

    1,715

     

     

     

    1,629

     

    Loss on marketable equity securities, net

     

     

    (8

    )

     

     

    (176

    )

    Change in fair value of warrant liability

     

     

    2,128

     

     

     

    —

     

    Foreign currency transaction loss, net

     

     

    (269

    )

     

     

    (544

    )

    Other income (expense), net

     

     

    (670

    )

     

     

    542

     

    Total other income (expenses)

     

     

    2,896

     

     

     

    1,451

     

     

     

     

     

     

    LOSS BEFORE INCOME TAXES

     

     

    (18,582

    )

     

     

    (23,282

    )

     

     

     

     

     

    Provision for income tax benefit

     

     

    —

     

     

     

    1,803

     

     

     

     

     

     

    NET LOSS

     

     

    (18,582

    )

     

     

    (21,479

    )

     

     

     

     

     

    Net (income) loss attributable to noncontrolling interest

     

     

    (27

    )

     

     

    (7

    )

     

     

     

     

     

    NET LOSS ATTRIBUTABLE TO LINEAGE

     

    $

    (18,609

    )

     

    $

    (21,486

    )

     

     

     

     

     

    Net loss per common share attributable to Lineage basic and diluted

     

    $

    (0.09

    )

     

    $

    (0.12

    )

     

     

     

     

     

    Weighted-average common shares used to compute basic and diluted net loss per common share

     

     

    200,193

     

     

     

    172,663

     

    LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES

    CONSOLIDATED STATEMENTS OF CASH FLOWS

    (IN THOUSANDS)

     

     

     

    Year Ended December 31,

     

     

    2024

     

    2023

    CASH FLOWS FROM OPERATING ACTIVITIES:

     

     

     

     

    Net loss attributable to Lineage

     

    $

    (18,609

    )

     

    $

    (21,486

    )

    Net loss attributable to noncontrolling interest

     

     

    27

     

     

     

    7

     

    Adjustments to reconcile net loss attributable to Lineage Cell Therapeutics, Inc.

    to net cash used in operating activities:

     

     

     

     

    Issuance costs for common stock warrant liabilities

     

     

    688

     

     

     

    —

     

    Loss on marketable equity securities, net

     

     

    8

     

     

     

    176

     

    Accretion of income on marketable debt securities

     

     

    (229

    )

     

     

    (679

    )

    Depreciation and amortization expense

     

     

    587

     

     

     

    562

     

    Change in right-of-use assets and liabilities

     

     

    (42

    )

     

     

    91

     

    Amortization of intangible assets

     

     

    22

     

     

     

    130

     

    Stock-based compensation

     

     

    5,077

     

     

     

    4,640

     

    Change in fair value of warrant liability

     

     

    (2,128

    )

     

     

    —

     

    Deferred income tax benefit

     

     

    —

     

     

     

    (1,803

    )

    Foreign currency remeasurement and other loss

     

     

    273

     

     

     

    600

     

    Changes in operating assets and liabilities:

     

     

     

     

    Accounts receivable

     

     

    106

     

     

     

    (446

    )

    Prepaid expenses and other current assets

     

     

    489

     

     

     

    (418

    )

    Accounts payable and accrued liabilities

     

     

    (1,681

    )

     

     

    (2,295

    )

    Deferred revenue

     

     

    (7,680

    )

     

     

    (7,645

    )

    Net cash used in operating activities

     

     

    (23,092

    )

     

     

    (28,566

    )

     

     

     

     

     

    CASH FLOWS FROM INVESTING ACTIVITIES:

     

     

     

     

    Proceeds from the sale of marketable equity securities

     

     

    18

     

     

     

    196

     

    Purchases of marketable debt securities

     

     

    (8,761

    )

     

     

    (16,403

    )

    Maturities of marketable debt securities

     

     

    7,000

     

     

     

    63,330

     

    Purchase of equipment

     

     

    (565

    )

     

     

    (674

    )

    Net cash (used in) provided by investing activities

     

     

    (2,308

    )

     

     

    46,449

     

     

     

     

     

     

    CASH FLOWS FROM FINANCING ACTIVITIES:

     

     

     

     

    Proceeds from employee options exercised

     

     

    229

     

     

     

    88

     

    Common shares received and retired for employee taxes paid

     

     

    (23

    )

     

     

    (37

    )

    Proceeds from sale of common shares under ATM, net of offering costs

     

     

    68

     

     

     

    6,426

     

    Proceeds from sale of common shares under registered direct financing, net of offering costs

     

     

    13,889

     

     

     

    —

     

    Proceeds from sale of common shares with warrants under registered direct financing, net of offering costs

     

     

    21,919

     

     

     

    —

     

    Payment of financed insurance premium

     

     

    (171

    )

     

     

    —

     

    Repayment of finance lease liabilities

     

     

    (54

    )

     

     

    (54

    )

    Net cash provided by financing activities

     

     

    35,857

     

     

     

    6,423

     

    Effect of exchange rate changes on cash, cash equivalents and restricted cash

     

     

    (95

    )

     

     

    (250

    )

    NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

     

     

    10,362

     

     

     

    24,056

     

     

     

     

     

     

    CASH, CASH EQUIVALENTS AND RESTRICTED CASH:

     

     

     

     

    At beginning of the period

     

     

    35,992

     

     

     

    11,936

     

    At end of the period

     

    $

    46,354

     

     

    $

    35,992

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250310327842/en/

    Lineage Cell Therapeutics, Inc. IR

    Ioana C. Hone

    ([email protected])

    (442) 287-8963

    Russo Partners – Media Relations

    Nic Johnson or David Schull

    ([email protected])

    ([email protected])

    (212) 845-4242

    Get the next $LCTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LCTX

    DatePrice TargetRatingAnalyst
    8/20/2024$4.00Buy
    Craig Hallum
    11/2/2022$5.00Outperform
    Robert W. Baird
    6/14/2022$4.00Buy
    B. Riley Securities
    8/19/2021$8.00Outperform
    Noble Capital Markets
    More analyst ratings

    $LCTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its first quarter 2025 financial and operating results on Tuesday, May 13, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Tuesday, May 13, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2025 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the conference call on May 13, 2025, by dialing (800) 7

      5/1/25 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium

      Fully Virtual Event Scheduled for June 27, 2025 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana Reeve Foundation, a non-profit organization dedicated to advancing innovative research and improving quality of life for individuals impacted by paralysis, are proud to collaborate and present the 3rd Annual Spinal Cord Injury Investor Symposium ("3rd SCIIS"). This year's event aims to bring together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived experience, patient and community advoc

      4/22/25 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)

      Lineage Participating in Panel Discussion of Novel Retina Drug Delivery Approaches at Eyecelerator@ Park City 2025 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage's Chief Executive Officer, has been invited to join presenters from REGENXBIO Inc., Regenerative Patch Technologies, LLC, Neurotech Pharmaceuticals, Inc., and others, as part of the "I Shall Be Released: Novel Drug Delivery Approaches for Glaucoma and Retina" panel at Eyecelerator@ Park City 2025. The panel will take place on Friday, May 2, 2025 from 12:30pm to 1:30pm M

      4/21/25 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    SEC Filings

    See more
    • Lineage Cell Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)

      5/1/25 9:09:09 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Lineage Cell Therapeutics Inc.

      DEFA14A - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)

      4/29/25 4:10:04 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Lineage Cell Therapeutics Inc.

      DEF 14A - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)

      4/29/25 4:05:15 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

      Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical   Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced updates to its 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS"). The 2nd SCIIS aims to accelerate development in SCI research and treatments by bringing together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived exp

      5/21/24 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture

      4/1/24 8:00:00 AM ET
      $LCTX
      $SYBX
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Lineage Announces Appointment of General Counsel

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it has appointed George A. Samuel III as Lineage's General Counsel and Corporate Secretary. Mr. Samuel will lead the Company's legal operations, bringing extensive corporate, transactional, intellectual property and commercial expertise which spans nearly 15 years across the life sciences and technology sectors as well as in private practice. "We are pleased to welcome George to our leadership team and look forward to his contributions as we build Lineage into a leading cell therapy and cell transplant comp

      9/1/21 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Lineage Cell Therapeutics Inc.

      SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)

      11/21/24 8:05:56 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Lineage Cell Therapeutics Inc. (Amendment)

      SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)

      2/8/24 6:57:07 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Lineage Cell Therapeutics Inc. (Amendment)

      SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)

      3/25/22 5:23:02 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Lineage Cell Therapeutics with a new price target

      Craig Hallum initiated coverage of Lineage Cell Therapeutics with a rating of Buy and set a new price target of $4.00

      8/20/24 8:32:59 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Robert W. Baird initiated coverage on Lineage Cell Therapeutics with a new price target

      Robert W. Baird initiated coverage of Lineage Cell Therapeutics with a rating of Outperform and set a new price target of $5.00

      11/2/22 6:28:33 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • B. Riley Securities initiated coverage on Lineage Cell Therapeutics with a new price target

      B. Riley Securities initiated coverage of Lineage Cell Therapeutics with a rating of Buy and set a new price target of $4.00

      6/14/22 7:59:45 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Broadwood Partners, L.P. bought $6,000,000 worth of shares (7,894,737 units at $0.76) (SEC Form 4)

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      1/28/25 7:49:41 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Howe Jill Ann bought $8,850 worth of shares (15,000 units at $0.59), increasing direct ownership by 143% to 25,500 units (SEC Form 4)

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      11/26/24 4:58:31 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • General Counsel Samuel George A. Iii bought $9,000 worth of shares (15,000 units at $0.60), increasing direct ownership by 209% to 22,184 units (SEC Form 4)

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      11/26/24 4:55:46 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by President and CEO Culley Brian M

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      3/12/25 5:30:54 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Howe Jill Ann

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      3/12/25 5:30:36 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by General Counsel and Secretary Samuel George A. Iii

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      3/12/25 5:30:11 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    Financials

    Live finance-specific insights

    See more
    • Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its first quarter 2025 financial and operating results on Tuesday, May 13, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Tuesday, May 13, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2025 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the conference call on May 13, 2025, by dialing (800) 7

      5/1/25 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its fourth quarter and full year 2024 financial and operating results on Monday, March 10, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Monday, March 10, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2024 financial and operating results and to provide a business update. Interested parties may access the conference call on Monday, March 10, 2025, by di

      3/5/25 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

      OpRegen® Granted Regenerative Medicine Advanced Therapy (RMAT) Designation From FDA ReSonance™ (ANP1) Preclinical Results Presented at 59th Annual Inner Ear Biology Workshop Added to 2024 Russell 3000® Index Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its third quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update. "We were delighted to see our partners' continued commitment to the OpRegen program, in this instance by seeking

      11/14/24 4:01:00 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care